Linked Life Data

20128819

Source:http://linkedlifedata.com/resource/pubmed/id/20128819

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20128819rdf:typepubmed:Citationlld:pubmed
pubmed-article:20128819lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C0205470lld:lifeskim
pubmed-article:20128819lifeskim:mentionsumls-concept:C1709510lld:lifeskim
pubmed-article:20128819pubmed:issue3lld:pubmed
pubmed-article:20128819pubmed:dateCreated2010-3-31lld:pubmed
pubmed-article:20128819pubmed:abstractTextWe previously reported that personalized peptide vaccine (PPV) therapy in combination with leutenizing hormone-releasing hormone (LH-RH) analog and estramustine phosphate in certain cases is safe and capable of inducing both immune responses and clinical responses for metastatic castration-resistant prostate cancer (CRPC) patients. In the present study, PPV monotherapy was given to CRPC patients. Twenty-three patients with metastatic CRPC were treated with PPV without any additional treatment modalities, including LH-RH analogs. Samples were analyzed for peptide-specific cytotoxic T-lymphocyte (CTL) precursor analysis and peptide-reactive IgG. Toxicity and immunological and clinical responses were assessed on a three-monthly basis. Seventeen patients were available for immunological and clinical evaluation. The vaccines were well tolerated, with grade 3 erythema at injection sites in only one patient. Augmentation of CTL or IgG responses to at least one of the peptides was observed in six of 17 (35%) and 15 of 17 (88%) patients tested, respectively. Among 57 peptides used, 9 and 36 peptides induced CTL and IgG responses, respectively. Delayed-type hypersensitivity reaction was observed in eight of 17 patients. More than 30% prostate-specific antigen (PSA) decline was observed in four of 17 patients. Of these, one patient achieved a complete PSA response and another patient showed a partial PSA response with profound shrinking of lymph node metastases and prostate. The overall median survival time was 24 months (range, 5-37 months). These results suggest that PPV monotherapy appears to be safe and capable of inducing peptide-specific immune responses and clinical responses in CRPC patients. This trial was registered with University Hospital Medical Information Network (UMIN) number R000003339.lld:pubmed
pubmed-article:20128819pubmed:languageenglld:pubmed
pubmed-article:20128819pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128819pubmed:citationSubsetIMlld:pubmed
pubmed-article:20128819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128819pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20128819pubmed:statusMEDLINElld:pubmed
pubmed-article:20128819pubmed:monthMarlld:pubmed
pubmed-article:20128819pubmed:issn1349-7006lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:YamadaAkiraAlld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:FujimotoKiyoh...lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:HiraoYoshihik...lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:ItohKyogoKlld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:MineTakashiTlld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:UemuraHirotsu...lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:KomatsuNobuka...lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:UejimaShigeya...lld:pubmed
pubmed-article:20128819pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:20128819pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20128819pubmed:volume101lld:pubmed
pubmed-article:20128819pubmed:ownerNLMlld:pubmed
pubmed-article:20128819pubmed:authorsCompleteYlld:pubmed
pubmed-article:20128819pubmed:pagination601-8lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:meshHeadingpubmed-meshheading:20128819...lld:pubmed
pubmed-article:20128819pubmed:year2010lld:pubmed
pubmed-article:20128819pubmed:articleTitleImmunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer.lld:pubmed
pubmed-article:20128819pubmed:affiliationDepartment of Urology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan. huemura@med.kindai.ac.jplld:pubmed
pubmed-article:20128819pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20128819pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed